Gameto vs Lyell Immunopharma

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (36 vs 36)
Gameto logo

Gameto

EmergingBioTech

Reproductive Medicine

Gameto raised $70M Series B in 2024 for its stem cell technology that dramatically reduces IVF stimulation duration from 10 days to 2–3 days, making fertility treatment faster, cheaper, and less invasive.

AI VisibilityBeta
Overall Score
D36
Category Rank
#97 of 198
AI Consensus
77%
Trend
stable
Per Platform
ChatGPT
32
Perplexity
32
Gemini
39

About

Gameto is revolutionizing in vitro fertilization by engineering ovarian granulosa cells from stem cells that can mature patient eggs in the lab, eliminating the lengthy and hormone-intensive stimulation protocols required by conventional IVF. The company's Fertilo technology co-incubates patient egg cells with Gameto's lab-grown granulosa cells, achieving maturation in 2–3 days versus the 10+ days of hormone injections that characterize standard IVF stimulation.

Full profile
Lyell Immunopharma logo

Lyell Immunopharma

EmergingBiotechnology

Cell Therapy

Lyell Immunopharma develops next-generation CAR-T cell therapies designed to overcome T cell exhaustion and treat solid tumors, the frontier of cell therapy.

AI VisibilityBeta
Overall Score
D36
Category Rank
#77 of 198
AI Consensus
91%
Trend
stable
Per Platform
ChatGPT
37
Perplexity
34
Gemini
37

About

Lyell Immunopharma is a clinical-stage cell therapy company founded in 2018 by Rick Klausner and publicly traded on Nasdaq. The company focuses on next-generation CAR-T therapies that address the key limitations of first-generation products, particularly the exhaustion and dysfunction of engineered T cells that limits efficacy especially against solid tumors. Lyell has developed proprietary T cell reprogramming technologies including gene overexpression approaches that maintain T cell stemness and fitness during manufacturing and after infusion. The company is applying these technologies to both hematological malignancies and solid tumors in a pipeline of clinical programs. Lyell has established a research collaboration with GlaxoSmithKline to combine cell therapy expertise. While first-generation CAR-T products have demonstrated remarkable responses in blood cancers, Lyell is focused on the much larger unmet need in solid tumors where current CAR-T therapies have shown limited efficacy. The company represents the scientific evolution of the cell therapy field toward more durable and broadly applicable treatments.

Full profile

AI Visibility Head-to-Head

36
Overall Score
36
#97
Category Rank
#77
77
AI Consensus
91
stable
Trend
stable
32
ChatGPT
37
32
Perplexity
34
39
Gemini
37
40
Claude
35
37
Grok
37

Key Details

Category
Reproductive Medicine
Cell Therapy
Tier
Emerging
Emerging
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Gameto
Reproductive Medicine
Only Lyell Immunopharma
Cell Therapy

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.